europe.chinadaily.com.cn
CIIE: A Platform for Global Healthcare Companies in China
The 7th China International Import Expo (CIIE) facilitates market entry for global pharmaceutical and healthcare companies, showcasing innovative therapies and connecting them with Chinese partners.
English
China
HealthChinaHealthcareInternational TradeInnovationMedicalExpo
EssilorluxotticaAmgenBaxterVantiveXinhua
Kok Leong LimBob BradwayIrene HsuChris Toth
- What new development is Baxter showcasing at this year's CIIE?
- Baxter's kidney care business, soon to be a standalone company called Vantive, will be unveiled at the CIIE, showcasing its commitment to China's healthcare market with the debut of its made-in-China Pris-Max platform. This highlights the expo as a launchpad for new ventures in the Chinese healthcare sector.
- How has the CIIE benefitted companies like EssilorLuxottica and Amgen?
- Companies like EssilorLuxottica, with its Stellest® contact lens, and Amgen, with its Lumakras™ and Evenity® medications, have successfully launched products in China after showcasing them at previous CIIEs, benefiting from the expo's spillover effects and the accelerated market access it provides.
- What is the main purpose of the 7th China International Import Expo (CIIE)?
- The 7th China International Import Expo (CIIE) in Shanghai, held from Nov 5 to 10, serves as a significant platform for global pharmaceutical and healthcare companies to connect with Chinese partners and stakeholders, facilitating market entry and commercialization of innovative therapies.
- What is the overall significance of the CIIE for the Chinese healthcare market?
- The CIIE's success in facilitating market entry and accelerating commercialization of medical solutions demonstrates its importance as a bridge between international companies and the Chinese healthcare industry. This contributes to improving access to innovative medicines and therapies for Chinese patients.
- What impact has the CIIE had on the clinical development and commercialization of medical products in China?
- The CIIE has enabled companies to accelerate clinical development and commercialization of their products in China by connecting them with the local ecosystem, resulting in faster approval processes and increased market reach. This allows companies to reach Chinese patients with unmet needs more efficiently.